Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization.
about
Comparison of the efficacy of recombinant human brain natriuretic peptide with saline hydration in preventing contrast-induced nephropathy in patients undergoing coronary angiography with or without concomitant percutaneous coronary interventionContemporary management of infrapopliteal peripheral arterial disease.The role of N--acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis.Neutrophil gelatinase-associated lipocalin (NGAL): a promising biomarker of contrast-induced nephropathy after computed tomography.Contrast-Induced Nephropathy: An "All or None" Phenomenon?Contrast Volume to Cystatin C-Based Glomerular Filtration Ratio Predicts the Risk of Contrast-Induced Nephropathy After Cardiac Catheterization.Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography.Risk score for the prediction of contrast-induced nephropathy in elderly patients undergoing percutaneous coronary intervention.Neutrophil-to-lymphocyte ratio predicts contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention.Neutrophil gelatinase-associated lipocalin as an early marker of contrast-induced nephropathy after coronary angiography.GRACE risk score predicts contrast-induced nephropathy in patients with acute coronary syndrome and normal renal function.Platelet-to-Lymphocyte Ratio Predicts Contrast-Induced Nephropathy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.Effect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCI.Serum neutrophil gelatinase-associated lipocalin and cystatin C are early biomarkers of contrast-induced nephropathy after coronary angiography in patients with chronic kidney disease.
P2860
Q36183555-69F22C7D-8669-43F7-AC57-4CB21FA9C6D3Q37855314-F43EDB0F-B839-45A3-9A3E-9C1A77AC848CQ38063188-ADD1AAAC-9A98-433F-A537-1263A07E417BQ38199743-3E9C6294-BB16-49D0-BDD8-158B3E130869Q38250041-3BD95788-47F9-40CC-B39E-76AEA5CB7112Q39628664-F2C36004-FF1F-4626-832F-6E5CB8AA3065Q41889657-782B3456-202B-499C-9AAE-CA115369F996Q43614019-290C6F9C-2B3A-451E-9029-87911BC6099FQ43688318-C2412759-BC75-469D-A7F5-5CBA4AE787FDQ44008816-C20850C9-5CA7-4C35-AA59-25663DD33222Q44314100-F3175032-B37A-4814-B0F1-11BFC1D1FCF7Q48086175-7730C1A7-EBA4-4239-AF59-1C367FBF20A2Q48352293-4064B57A-EFC6-42D4-A808-9B8B28F1045AQ51072091-D89F0ECC-0AB2-4D07-A0A2-E7D6AE484EB5
P2860
Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Impact of contrast-induced nep ...... going cardiac catheterization.
@en
Impact of contrast-induced nep ...... going cardiac catheterization.
@nl
type
label
Impact of contrast-induced nep ...... going cardiac catheterization.
@en
Impact of contrast-induced nep ...... going cardiac catheterization.
@nl
prefLabel
Impact of contrast-induced nep ...... going cardiac catheterization.
@en
Impact of contrast-induced nep ...... going cardiac catheterization.
@nl
P2093
P2860
P356
P1433
P1476
Impact of contrast-induced nep ...... going cardiac catheterization.
@en
P2093
Fumihiko Miyake
Haruki Musha
Kensuke Kawasaki
Masahiro Yamauchi
Taishi Mikami
Yuki Ishibashi
P2860
P304
P356
10.1177/0003319710379108
P577
2010-11-01T00:00:00Z